A REVIEW OF NUTRACEUTICALS: EXPLORING THE ROLE IN MEDICINE

Shashank Singh[1*], Mohd. Wasiullah[2], Piyush Yadav[3]

1. Research Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, U.P, India.
2. Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, U.P, India.
3. Head, Department of Pharma: Chemistry, Prasad Institute of Technology, Jaunpur, U.P, India.

Abstract

Derived from the words "nutrition" and "pharmaceutical," the phrase "nutritraceuticals" has become a prominent area at the nexus of food and medicine. Nutraceuticals are becoming more widely acknowledged for their ability to prevent chronic diseases, assist therapeutic interventions, and improve general well-being as scientific knowledge of diet-related health grows. The classifications, modes of action, and increasing significance of nutraceuticals in modern medicine are all examined in this examination of the field's changing landscape. Targeted advantages like antioxidant, anti-inflammatory, anti-cancer, cardioprotective, and neuroprotective qualities are provided by the wide variety of nutraceuticals, which include dietary supplements, functional foods, herbal products, and isolated nutrients. Nutraceuticals act holistically, frequently enhancing cellular function and metabolic pathways, in contrast to traditional medications, which are frequently produced and target certain symptoms or illnesses. The line separating food from medication is still blurred, though, as national regulatory systems vary greatly and many claims are still awaiting scientific confirmation.

Keywords: *Nutraceuticals, Preventive Medicines, Anti- Inflammatory Effects, Skin health, Medicine*

Corresponding Author

Shashank Singh, Research Scholar
Prasad Institute of Technology, Jaunpur, U.P
Received: 22/02/2026
Revised: 28/02/2026
Accepted: 11/03/2026
DOI: http://doi.org/10.66204/GJPSR.397-2026-2-3-4

How to Cite
Singh S , Wasiullah M, Yadav P, Yadav V. A review of nutraceuticals: exploring the role in medicine. *Global Journal of Pharmaceutical and Scientific Research*. 2026;2(3):397–418. ISSN: 3108-0103. http://doi.org/10.66204/GJPSR.397-2026-2-3-4

1. Introduction

The idea of nutraceuticals has developed at the nexus of pharmacology and nutrition, reflecting the increasing understanding that diet is essential for disease prevention, therapeutic support, and maintaining health. Vitamins, minerals, polyphenols, carotenoids, fatty acids, probiotics, and herbal extracts are examples of nutraceuticals, which are generally characterized as bioactive substances derived from food sources that offer medicinal or health advantages beyond basic nutrition (Biesalski, 2017). Their natural origin, multi-targeted activities, and potential for long-term usage set them apart from traditional medications and make them appealing.

The need for preventative and adjunctive measures has increased in recent decades due to the worldwide burden of chronic diseases, such as diabetes, cancer, neurodegenerative diseases, metabolic syndrome, and cardiovascular problems. According to Kumar et al. (2017), nutraceuticals present a promising way to improve quality of life, improve therapeutic outcomes, and reduce the risk of disease. The scientific foundation for their usage has been reinforced by developments in formulation technologies, such as liposomal delivery and nanoencapsulation, as well as thorough clinical testing.

Nutraceuticals have a lot of potential, but they also have a lot of drawbacks, such as inconsistent bioavailability, inconsistent dosage, safety issues, unclear regulations, and scant clinical data for many chemicals. In order to guarantee efficacy and consumer safety, it has become more and more clear that evidence-based validation, quality assurance, and standardized rules are required (Bhattacharyya et al., 2018).

With regard to the classification, sources, methods of action, therapeutic functions, formulation strategies, safety considerations, clinical data, regulatory frameworks, market trends, and problems of nutraceuticals, this paper attempts to give a thorough overview. The study outlines future directions for research and clinical use while highlighting the advantages and disadvantages of nutraceuticals in contemporary medicine by synthesizing existing knowledge.

2. Classification of Nutraceuticals

Nutraceuticals are categorized according to their place of origin and usefulness in promoting health and preventing illness. Conventional nutraceuticals are bioactive substances found naturally in foods and medicinal plants that have been shown to be safe and effective (Biesalski, 2016).

2.1 Traditional Nutraceuticals

These include essential nutrients and plant-derived compounds that support physiological homeostasis and reduce disease risk (Pandey & Rizvi, 2009).

2.1.1 Nutrients (Vitamins, Minerals, and Amino Acids)

Vitamins serve as cofactors and antioxidants; for instance, vitamin D promotes bone and immunological health, while vitamins C and E lessen oxidative stress (Holick, 2007; Kaur & Kapoor, 2001). Enzymatic activity, immunology, and metabolism all depend on minerals like zinc, magnesium, calcium, and iron (Calder, 2020; DiNicolantonio et al., 2018). Glutamine and BCAAs are two examples of amino acids that support immunological response, gastrointestinal health, and protein synthesis (Wu, 2013).

2.1.2 Herbal and Botanical Products

Bioactive phytochemicals with anti-inflammatory, anti-cancer, and antioxidant qualities, including polyphenols, flavonoids, and terpenoids, are found in herbal nutraceuticals (Pandey & Rizvi, 2009). The pharmacological benefits of curcumin, resveratrol, and green tea catechins are noteworthy; yet, their widespread usage is restricted by their variability, lack of standardization, and few clinical trials (Gupta et al., 2012; Baur & Sinclair, 2006).

2.2 Non-Traditional Nutraceuticals

Non-traditional nutraceuticals are modified or engineered foods enriched to provide specific health benefits (Roberfroid, 2002).

2.2.1 Fortified Foods

Fortified foods deliver vitamins, minerals, fatty acids, or probiotics to prevent deficiencies and improve health outcomes (Allen et al., 2006). Examples include vitamin D-fortified milk, folic acid–fortified flour, and omega-3-enriched products, which have proven clinical benefits (Crider et al., 2011; Calder, 2017).

2.2.2 Recombinant and Genetically Modified Nutraceuticals

Golden rice and genetically modified probiotics are examples of biotechnologically created nutraceuticals that are designed to provide bioactive molecules with improved stability and efficacy. Before widespread implementation, comprehensive clinical study is necessary due to safety, ethical, and regulatory considerations (Davies, 2007; Foligné et al., 2013).

2.3 Classification Based on Chemical Nature

Chemical classification links molecular structure to biological function, guiding disease prevention and therapeutic use (Shahidi, 2012).

- **Polyphenols:** Plant secondary metabolites that have anti-inflammatory, cardioprotective, antioxidant, and anticancer properties include flavonoids, phenolic acids, and stilbenes (Pandey & Rizvi, 2009; Scalbert et al., 2005).
- **Carotenoids:** As antioxidants and precursors of vitamin A, lipophilic pigments such as lutein, zeaxanthin, lycopene, and β-carotene improve immunity, eyesight, and lower the risk of cancer (Krinsky et al., 2003; Rao & Rao, 2007).
- **Fatty Acids:** Omega-3 polyunsaturated fatty acids (EPA, DHA) boost neuroprotection, enhance cardiovascular health, and reduce inflammation (Calder, 2017; Mozaffarian & Wu, 2011).
- **Probiotics and Prebiotics:** Live microorganisms and indigestible fibers that improve immunity, metabolism, and gut microbiota; synbiotics have the potential to be therapeutically synergistic (Hill et al., 2014; Sanders et al., 2019).

Table 1: Classification and Examples of Nutraceuticals

Category	Subcategory	Examples
Traditional	Nutrients	Vitamins (A, C, D), Minerals (Calcium, Iron), Amino acids
Traditional	Herbal & Botanical	Turmeric, Ginkgo biloba, Green tea extract
Non-Traditional	Fortified Foods	Omega-3 enriched milk, Vitamin D fortified cereals
Non-Traditional	Recombinant/GM	Genetically modified probiotics, biofortified crops
Based on Chemical Nature	Polyphenols	Flavonoids, Resveratrol
Based on Chemical Nature	Carotenoids	Beta-carotene, Lycopene
Based on Chemical Nature	Fatty Acids	Omega-3, Omega-6
Based on Chemical Nature	Probiotics/Prebiotics	Lactobacillus, Inulin

Figure 1: Classification and Sources of Nutraceuticals

3. Sources of Nutraceuticals

Nutraceuticals come from both natural and artificial sources, each of which offers unique bioactive substances with potential medical applications. Understanding compositional variety, safety, and therapeutic application is facilitated by source-based classification (Shahidi, 2012).

3.1 Plant-Based Sources

Polyphenols, flavonoids, carotenoids, and dietary fibers with anti-inflammatory, anti-cancer, cardioprotective, and antioxidant qualities are abundant in plants (Pandey & Rizvi, 2009). Fruits, vegetables, whole grains, herbs, and spices are typical sources. By reducing oxidative stress and inflammation, compounds including curcumin, resveratrol, catechins, and quercetin provide health advantages; high consumption is associated with a lower risk of cancer, diabetes, and cardiovascular disease (Scalbert et al., 2005; Liu, 2013).

3.2 Animal-Based Sources

Omega-3 fatty acids, bioactive peptides, vitamins, and minerals that support immunity, metabolism, and neurological function are found in animal-derived nutraceuticals (Calder, 2017). Eggs give phospholipids, lutein, and choline for brain and lipid metabolism; dairy products contain antihypertensive peptides; and fish oils provide EPA and DHA for

cardioprotection (Korhonen & Pihlanto, 2006). Use may be restricted by cost, sustainability, and dietary constraints even with excellent bioavailability.

3.3 Microbial and Marine Sources

Lactobacillus, Bifidobacterium, and Saccharomyces probiotics improve immunity and intestinal health (Hill et al., 2014). Carotenoids, polysaccharides, omega-3 fatty acids, and sterols with antioxidant, anti-obesity, and anticancer properties are found in marine algae, seaweeds, and microalgae (Ganesan et al., 2020). Vitamins, enzymes, and bioactive peptides are also consistently produced by microbial fermentation, which makes them useful for pharmaceutical and nutraceutical applications.

3.4 Synthetic and Semi-Synthetic Sources

Precise dosing and large-scale production are made possible by synthetic nutraceuticals, which include chemically generated vitamins, amino acids, and fatty acids as well as semi-synthetic derivatives altered for improved absorption and stability (Ribeiro et al., 2019; Shahidi, 2012). However, consumer perception, safety assessment, and regulatory scrutiny continue to be obstacles that call for strict quality control and clinical validation.

4. Mechanisms of Action of Nutraceuticals

In order to prevent broad-spectrum diseases, nutraceuticals generally operate on several targets at once through a variety of molecular pathways that include oxidative stress, inflammation, immunology, metabolism, and gene regulation (Shahidi, 2012).

4.1 Antioxidant Mechanisms

Nutraceuticals guard against oxidative damage linked to cancer, neurological diseases, and cardiovascular disorders by boosting endogenous antioxidant mechanisms and neutralizing reactive oxygen species (ROS) (Halliwell & Gutteridge, 2015). Selenium, carotenoids, vitamins C and E, and polyphenols either directly scavenge ROS or activate Nrf2 to upregulate enzymes such as glutathione peroxidase, catalase, and superoxide dismutase (Pandey & Rizvi, 2009; Kensler et al., 2007).

4.2 Anti-Inflammatory Pathways

By altering important signaling pathways, nutraceuticals lessen chronic inflammation. Together, curcumin, omega-3 fatty acids, and flavonoids reduce tissue inflammation and

improve outcomes in inflammatory illnesses by inhibiting NF-κB, suppressing pro-inflammatory cytokines, and downregulating COX-2 and iNOS (Gupta et al., 2012; Calder, 2017).

4.3 Immunomodulatory Effects

By promoting immune cell development, cytokine signaling, and gut barrier integrity, vitamins (A, C, D, and E), zinc, selenium, polyphenols, and probiotics improve immunological function. In particular, probiotics increase regulatory T-cell activity, which helps lower the risk of infection, enhance vaccination response, and treat immune-related conditions (Hill et al., 2014; Calder, 2020).

4.4 Metabolic Regulation

Nutraceuticals affect energy balance, insulin sensitivity, and the metabolism of fats and carbohydrates. While fibers and prebiotics support gut microbiota and glucose homeostasis, helping with obesity, diabetes, and cardiovascular health, polyphenols like resveratrol and catechins activate AMPK and PPARs to improve fatty acid oxidation and insulin responsiveness (Baur & Sinclair, 2006; Mozaffarian & Wu, 2011).

4.5 Gene Expression and Epigenetic Modulation

Certain nutraceuticals affect aging, cancer, and inflammation pathways by influencing gene expression and epigenetics through DNA methylation, histone modification, and microRNA regulation. Histone deacetylases and DNA methyltransferases are regulated by resveratrol, sulforaphane, and curcumin, underscoring their promise in personalized and preventative treatment (Fenech et al., 2011; Link et al., 2010).

Table 2: Mechanisms of Action of Nutraceuticals

Nutraceutical	Mechanism	Biological Target	Therapeutic Effect
Curcumin	Anti-inflammatory	NF-κB pathway	Reduces chronic inflammation
Resveratrol	Antioxidant	SIRT1, ROS scavenging	Cardioprotection, longevity
Omega-3 fatty acids	Lipid modulation	PPARs, eicosanoid pathways	Reduces triglycerides, anti-inflammatory
Probiotics	Gut microbiota modulation	Intestinal epithelium, immune cells	Improves GI health, reduces diarrhea
Green tea catechins	Metabolic regulation	AMPK activation	Improves insulin sensitivity, lipid profile



Figure 2: Mechanisms of Action of Nutraceuticals

5. Role of Nutraceuticals in Disease Prevention and Management

Through their multi-targeted biological effects, nutraceuticals provide therapeutic and disease-preventive benefits, occupying a crucial interface between medication and nutrition. Nutraceuticals have pleiotropic effects, which makes them especially useful in complex chronic conditions, in contrast to traditional medications that frequently act on single molecular targets. In addition to normal medical therapies, they also have a role in primary prevention, attenuation of disease development, and supplementary therapy.

5.1 Cardiovascular Disorders

The primary cause of death worldwide is still cardiovascular diseases (CVDs), and nutraceuticals have shown great promise in reducing a number of cardiovascular risk factors. By modifying eicosanoid production, omega-3 polyunsaturated fatty acids (PUFAs) enhance endothelial function, decrease platelet aggregation, and have anti-inflammatory effects (Kris-Etherton et al., 2002). Through nitric oxide-mediated vasodilation and the inhibition of oxidative LDL modification, plant-derived polyphenols, such as flavonoids and phenolic acids, improve vascular homeostasis (Vauzour et al., 2010).

By reducing intestinal cholesterol absorption and bile acid reabsorption, dietary fibers and phytosterols lower serum cholesterol levels and diminish the risk of atherosclerosis (Jones et al., 2014). Regular consumption of nutraceutical-enriched diets is an effective non-

pharmacological strategy for reducing cardiovascular risk, especially in high-risk populations and early-stage disease, according to clinical and epidemiological studies.

5.2 Diabetes and Metabolic Syndrome

By addressing oxidative stress, dyslipidemia, insulin resistance, and chronic inflammation, nutraceuticals are important in the treatment of diabetes and metabolic syndrome. By modifying insulin receptor signaling and the expression of the glucose transporter (GLUT4), polyphenols like quercetin and catechins enhance glucose absorption (Hanhineva et al., 2010). Improved glycemic control is the outcome of berberine and other alkaloids activating AMP-activated protein kinase (AMPK), a crucial regulator of glucose and lipid metabolism (Turner et al., 2008). Prebiotics and synbiotics are two examples of gut microbiota-modulating nutraceuticals that lower metabolic endotoxemia and low-grade inflammation linked to obesity and insulin resistance (Cani et al., 2009). The significance of nutraceuticals as metabolic regulators with systemic and microbiome-mediated effects is underscored by these findings.

5.3 Cancer Prevention and Adjuvant Therapy

By disrupting several phases of carcinogenesis, such as initiation, promotion, and progression, nutraceuticals help prevent cancer. Phytochemicals like polyphenols, carotenoids, and isothiocyanates improve DNA repair processes, inhibit pro-inflammatory transcription factors like NF-κB and STAT3, and modify phase I and phase II detoxification enzymes (Aggarwal & Shishodia, 2006).

By making tumor cells more sensitive to chemotherapy and radiation while shielding healthy tissues from oxidative damage, nutraceuticals may improve treatment results in adjuvant situations (Greenlee et al., 2017). To prevent negative interactions with traditional anticancer medications, their usage in oncology must be carefully considered, underscoring the necessity of evidence-based integration.

5.4 Neurodegenerative Disorders

Progressive neuronal loss brought on by oxidative stress, neuroinflammation, mitochondrial malfunction, and protein aggregation is a hallmark of neurodegenerative disorders. By focusing on these interrelated pathways, nutraceuticals provide neuroprotection. While polyphenols like resveratrol trigger neuroprotective signaling pathways like sirtuins and Nrf2-mediated antioxidant responses, omega-3 fatty acids promote synaptic membrane fluidity and neurotransmission (Spencer, 2010).

Elevated homocysteine levels are linked to neurodegeneration and cognitive decline, and B-complex vitamins are essential for homocysteine metabolism (Smith & Refsum, 2016). Long-term consumption of neuroprotective nutraceuticals has been linked to a lower risk of neurodegenerative diseases and a delay in cognitive aging.

5.5 Gastrointestinal Disorders

Because the gastrointestinal system is directly exposed to food bioactive substances, it is a prime target for nutraceutical intervention. Probiotics and prebiotics are useful in treating inflammatory and functional bowel disorders because they modulate mucosal immune responses, increase the integrity of the epithelial barrier, and restore microbial balance (Sanders et al., 2019).

By modifying gut-associated lymphoid tissue (GALT) and preventing the synthesis of pro-inflammatory cytokines, polyphenols and fibers that produce short-chain fatty acids have anti-inflammatory effects (Valdés et al., 2015). These nutraceuticals may lower the incidence of colorectal cancer and persistent intestinal inflammation while also promoting gut homeostasis.

5.6 Bone and Joint Health

By affecting cartilage integrity, mineralization, and bone remodeling, nutraceuticals promote skeletal health. By controlling osteoblast and osteoclast activity, vitamin K, magnesium, and bioactive peptides preserve bone mass and lower the risk of fracture (Rondanelli et al., 2021). While anti-inflammatory nutraceuticals lessen joint deterioration in osteoarthritis, collagen peptides promote extracellular matrix production in cartilage and bone. Recent research indicates that certain polyphenols may be useful in treating age-related skeletal problems by preventing osteoclastogenesis and oxidative bone loss (Weaver et al., 2016).

5.7 Immune System Support

By influencing immune cell development, cytokine signaling, and antioxidant defenses, nutraceuticals improve immunological competence. While vitamin D controls innate and adaptive immunological responses through vitamin D receptor-mediated gene expression, micronutrients like zinc and selenium are crucial for lymphocyte growth and redox equilibrium (Gombart et al., 2020).

Probiotic nutraceuticals lower susceptibility to infections, boost immunoglobulin A synthesis, and improve mucosal immunity. These immunomodulatory effects are especially important for people with weakened immune systems and older populations.

6. Formulation and Delivery Systems

Nutraceuticals' formulation and distribution have a significant impact on their medicinal efficacy. Clinical efficacy is limited by the poor solubility, instability, fast metabolism, and low bioavailability of many drugs. The goal of formulation advancements is to close the gap between medicines and nutraceuticals by enhancing stability, absorption, targeted distribution, and controlled release.

6.1 Conventional Dosage Forms

Because they are easy to use, affordable, and well-liked by consumers, traditional forms like as tablets, capsules, powders, and liquids are still often utilized. While powders and liquids offer flexibility and simplicity of administration for pediatric and elderly populations, tablets and capsules offer accurate dose and stability (Chaudhary et al., 2011). Nevertheless, they frequently fall short in addressing low solubility, GI tract degradation, and absorption variability (McClements & Xiao, 2014).

6.2 Advanced Drug Delivery Systems

Advanced systems enhance bioactive protection, absorption, and controlled release.

6.2.1 Nanoformulations

According to Patel et al. (2018), intestinal absorption, permeability, and solubility are all enhanced by nanoscale carriers such nanoparticles, nanoemulsions, and nanocrystals. Polyphenols, carotenoids, and omega-3 fatty acids can be nanoencapsulated to improve site-specific delivery, bioavailability, and antioxidant activity while lowering dosage requirements (Martins et al., 2020).

6.2.2 Liposomes

Hydrophilic and lipophilic nutraceuticals are encapsulated in liposomes, which are phospholipid vesicles that improve cellular absorption and shield them from destruction (Mozafari et al., 2008). Biocompatibility and membrane fusion enable oral and topical distribution of liposomal vitamins and antioxidants, which exhibit enhanced pharmacokinetics and efficacy (Akbarzadeh et al., 2013).

6.2.3 Microencapsulation

Nutraceuticals are trapped in lipid or polymeric matrices by microencapsulation, which allows for regulated release and protection from environmental stress. Commonly employed methods include coacervation and spray drying (de Vos et al., 2010). Probiotics, essential oils, and polyunsaturated fatty acids benefit greatly from this, since it enhances their stability, targeted release, and sensory qualities (Anal & Singh, 2007).

6.3 Bioavailability and Stability Challenges

Poor solubility, metabolism, and dietary interactions continue to be major obstacles to bioavailability (Manach et al., 2005). Probiotics may become unviable in stomach circumstances, although polyphenols and carotenoids are thoroughly digested (Tripathi & Giri, 2014). Careful excipient selection, packing, and delivery design are crucial since stability problems like oxidation, hydrolysis, and photodegradation further complicate formulation.



Figure 3: Formulation and Delivery Systems for Nutraceuticals

7. Safety, Efficacy, and Toxicological Considerations

Although nutraceuticals are widely perceived as safe, "natural" does not guarantee safety. Variability in composition, bioavailability, and pharmacodynamic effects necessitates careful consideration of dose, interactions, toxicity, and quality control to ensure efficacy without harm (Singh et al., 2018).

7.1 Dose Optimization and Therapeutic Window

Achieving benefits while avoiding harm requires optimal dose. Due to a dearth of clinical data, many nutraceuticals lack clearly defined therapeutic windows (Kumar et al., 2017). High concentrations of fat-soluble vitamins (A, D, E, and K) can build up in tissues and result in bleeding problems, hypercalcemia, or hepatotoxicity (Schmid et al., 2019). Advanced delivery methods and nanoformulations may improve bioavailability, necessitating a reassessment of traditional dose ranges (McClements, 2018).

7.2 Drug–Nutraceutical Interactions

Nutraceuticals can affect drug absorption, metabolism, and excretion through CYP enzymes, P-glycoprotein, or GI pH changes (Posadzki et al., 2013). Examples include:

- Green tea catechins may reduce chemotherapy efficacy (Cheng et al., 2010).
- Ginkgo biloba can increase bleeding risk with anticoagulants (Izzo & Ernst, 2009).
- St. John's wort induces CYP3A4, lowering plasma concentrations of immunosuppressants and antivirals (Markowitz et al., 2003).

7.3 Adverse Effects and Toxicity

Despite being typically well tolerated, prolonged or high-dose use may result in allergies, hepatotoxicity, nephrotoxicity, or gastrointestinal problems (Posadzki et al., 2013). For instance, too much iron (oxidative stress), vitamin A (hepatotoxicity, teratogenicity), or tainted herbal products. Toxicological research is still crucial, particularly for nanoformulations (Singh et al., 2018).

7.4 Quality Control and Standardization Issues

Safety and effectiveness are impacted by variations in formulations, extraction techniques, and raw ingredients. It is essential to standardize employing stability testing, bioactivity assays, and marker compound quantification (Bhattacharyya et al., 2018). Product dependability is guaranteed by GMP compliance, batch testing, and regulatory approvals (FDA, EFSA, WHO). Analytical techniques include spectrophotometry, LC-MS/MS, and HPLC are frequently used (Cowan et al., 2020).

8. Clinical Evidence and Therapeutic Validation

An increasing body of research from preclinical investigations, randomized controlled trials, and meta-analyses supports the clinical validation of nutraceuticals. Several nutraceuticals' antioxidant, anti-inflammatory, and metabolic regulating properties have been demonstrated in experimental studies, establishing biological plausibility and serving as the foundation for human studies (Biesalski, 2017; Aggarwal & Shishodia, 2006). Omega-3 fatty acids have been shown to improve cardiovascular risk factors and lower triglycerides, while vitamin D and calcium have been shown to lower the incidence of fracture in older populations (Mozaffarian & Wu, 2011; Avenell et al., 2014).

Probiotics have been shown to consistently enhance gut health and symptom severity in cases of gastrointestinal illnesses such antibiotic-associated diarrhea and irritable bowel syndrome, according to moderate evidence (Didari et al., 2015; Sanders et al., 2019). Although results vary depending on formulation, dosage, and study design, polyphenols such as curcumin,

green tea catechins, and resveratrol have demonstrated promising adjunctive benefits in inflammatory, metabolic, and cancer-related conditions (Gupta et al., 2012; Yang et al., 2014; Baur & Sinclair, 2006).

Despite promising results, small sample sizes, brief study periods, and the absence of standardized nutraceutical formulations continue to hinder clinical translation. These difficulties show that before a treatment is widely adopted, extensive, well planned clinical trials are required to demonstrate consistent efficacy, ideal dosage, and long-term safety (Kumar et al., 2017; Shahidi, 2012).

Table 3: Clinically Validated Nutraceuticals

Nutraceutical	Clinical Indication	Evidence Level	Key Findings
Omega-3 fatty acids	Hypertriglyceridemia, CVD	Strong (multiple RCTs, meta-analyses)	Lowered triglycerides, anti-inflammatory, cardioprotective
Vitamin D + Calcium	Osteoporosis	Strong	Reduced fracture risk in elderly populations
Curcumin	Inflammatory disorders, cancer adjunct	Moderate	Anti-inflammatory, improves quality of life in RA and CRC adjunct therapy
Probiotics	IBS, antibiotic-associated diarrhea	Moderate-Strong	Improved gut microbiota, reduced diarrhea duration and severity
Green tea catechins	Metabolic syndrome, cancer prevention	Moderate	Modest improvement in weight, insulin resistance, and lipid profiles

9.1 Global Regulatory Framework

FDA (USA)

The Dietary Supplement Health and Education Act (DSHEA, 1994) classifies nutraceuticals as "Dietary Supplements" in the United States. Before a product is marketed, manufacturers are in charge of making sure it is safe and properly labeled. Dietary supplements do not need pre-market approval like pharmaceuticals do, but the FDA may step in if a product is adulterated, mislabeled, or dangerous (Geller et al., 2015).

Key regulatory points include:

- Good Manufacturing Practices (GMP) for dietary supplements
- Mandatory reporting of serious adverse events

- Prohibition of disease claims without FDA approval

EFSA (Europe)

Nutraceutical safety, labeling, and health claims are governed by the European Food Safety Authority (EFSA) in the EU. The EU Nutrition and Health Claims Regulation (EC No. 1924/2006) governs nutraceuticals, which are typically categorized as "food supplements" (Gibson et al., 2017).

- Health claims must be scientifically substantiated, based on human studies and peer-reviewed evidence.
- Novel foods, such as new bioactive compounds or fortified products, require pre-market approval.
- EFSA also evaluates contaminants, allergens, and permissible limits of active ingredients to ensure safety.

FSSAI (India)

Under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food, and Novel Food) Regulations, 2016, the Food Safety and Standards Authority of India (FSSAI) governs nutraceuticals, functional foods, and dietary supplements in India.

- Manufacturers must obtain licenses and ensure adherence to GMP.
- Labels must include composition, recommended dosage, manufacturing and expiry dates, and any warnings.
- Claims regarding disease prevention or treatment are strictly prohibited unless scientifically validated (Sharma et al., 2020).

9.2 Labeling, Claims, and Compliance

Accurate labeling is critical to consumer trust and safety. Regulatory authorities require:

- Ingredient disclosure and dosage per serving
- Health and nutritional claims substantiated by scientific evidence
- Warnings for potential side effects, contraindications, and allergen information

Unsupported claims and mislabeling continue to be serious issues. For example, surveys conducted across several nations have shown supplements with inconsistent amounts of active ingredients, unreported allergies, or false claims on illness prevention (Dickinson et al., 2014).**9.3 Challenges in Regulation and Enforcement**

Despite established frameworks, nutraceutical regulation faces several challenges:

1. **Global variability**: Different definitions and regulatory requirements lead to inconsistent standards across countries (Sahoo et al., 2018).
2. **Lack of pre-market evaluation**: Many nutraceuticals enter markets without rigorous clinical validation.
3. **Quality inconsistency**: Variations in raw material sourcing, extraction, and manufacturing may result in batch-to-batch differences.
4. **Consumer perception**: The belief that "natural = safe" complicates regulatory enforcement and adverse event reporting.
5. **Evolving bioactive ingredients**: Novel nutraceuticals, nanoformulations, and genetically engineered compounds challenge existing regulations.

Addressing these challenges requires international harmonization of standards, robust quality control, post-market surveillance, and stricter enforcement mechanisms.

Table 4: Global Regulatory Framework and Quality Standards for Nutraceuticals

Regulatory Authority	Region	Classification of Nutraceuticals	Key Regulations	Labeling & Claim Requirements	Quality Control Requirements
FDA	USA	Dietary Supplements	DSHEA 1994	Cannot claim to diagnose, treat, cure, or prevent disease; structure/function claims allowed	Good Manufacturing Practices (GMP); Adverse event reporting
EFSA	Europe	Food Supplements	EC 1924/2006 (Nutrition & Health Claims Regulation)	Health claims must be scientifically substantiated; novel foods require pre-market approval	Safety assessment, contaminant limits, standardized bioactive content
FSSAI	India	Health Supplements / Nutraceuticals	FSS (Health Supplements, Nutraceuticals, Foods for Special Dietary Use) Regulations 2016	Ingredient disclosure, recommended dosage, warnings; disease claims prohibited	Licensing, GMP compliance, batch testing, labeling verification
TGA	Australia	Complementary Medicines	Therapeutic Goods Act 1989	Claims limited to evidence-based benefits; pre-market registration for therapeutic claims	GMP, quality and stability testing, adverse event reporting

10. Market Trends and Future Prospects

Over the past 20 years, the nutraceutical industry has experienced unheard-of growth because to advancements in formulation and delivery technologies, aging populations, and growing consumer awareness of preventative health. Nutraceuticals' future is at the nexus of cutting-edge delivery methods, individualized nutrition, and scientific validation.

10.1 Global Nutraceutical Market Overview

The global nutraceutical market has expanded rapidly, with current estimates exceeding USD 350 billion in 2025, driven by increasing demand for functional foods, dietary supplements, and fortified beverages (Grand View Research, 2023). Key drivers include:

- Rising prevalence of chronic diseases (cardiovascular, diabetes, obesity)
- Increased consumer focus on preventive healthcare
- Expansion of e-commerce and health-focused retail platforms
- Technological innovations enabling enhanced bioavailability and stability

The market is dominated by North America, Europe, and Asia-Pacific because of their strong regulatory environments, high levels of disposable income, and health consciousness. Urbanization and changes in lifestyle are driving rapid adoption in emerging nations (Srinivasan et al., 2021).

10.2 Emerging Trends and Innovations

Several innovations are shaping the future nutraceutical landscape:

1. **Nano- and microformulations**: Bioactives including probiotics, omega-3 fatty acids, and curcumin have improved bioavailability, targeted administration, and controlled release (McClements, 2018).
2. **Fortified functional foods**: Integration of bioactive compounds into everyday foods (e.g., omega-3 enriched dairy, plant sterol-enriched spreads).
3. **Plant-based and sustainable sources**: Algae, mushrooms, and microbial-derived bioactives are gaining traction for sustainability and health benefits.
4. **Digital health and tracking**: Use of apps and wearables to monitor nutrient intake and optimize supplementation (Kapoor et al., 2022).
5. **Combination formulations**: Multi-target nutraceuticals addressing metabolic syndrome, immunity, and cognitive function in a single product.

These innovations demonstrate a shift from generalized supplementation to precision, convenience, and scientifically validated products.

10.3 Role of Personalized Nutrition

A paradigm shift in the use of nutraceuticals is represented by personalized nutrition. Nutraceutical interventions can be customized to meet specific needs by combining genomes, metabolomics, microbiome analysis, and lifestyle data, increasing efficacy and minimizing side effects (Celis-Morales et al., 2015).

- **Genetic profiling**: Determines optimal micronutrient requirements and susceptibility to deficiencies.
- **Microbiome-guided supplementation**: Personalizes probiotics and prebiotics for gut health.
- **Digital platforms**: Enable real-time dietary monitoring and adaptive nutraceutical recommendations.

Future product development is anticipated to be dominated by personalized nutraceuticals, particularly in the markets for metabolic, anti-aging, and cognitive health.

10.4 Future Research Directions

Despite rapid growth, several research gaps remain:

1. **Long-term safety and efficacy studies**: Few nutraceuticals have extensive longitudinal human data.
2. **Mechanistic studies**: Need for elucidation of multi-target pathways and interactions with drugs.
3. **Standardization and quality assurance**: Development of international protocols for bioactive quantification and stability testing.
4. **Emerging bioactives**: Exploration of marine, microbial, and plant-derived novel compounds.
5. **Regulatory harmonization**: Cross-border guidelines to ensure safety, efficacy, and consumer trust.

The next-generation nutraceutical market will be driven by the integration of cutting-edge delivery systems, individualized strategies, and evidence-based validation, guaranteeing a sustainable, efficient, and customer-focused sector.

11. Challenges and Limitations of Nutraceuticals

Nutraceuticals are becoming more and more popular, yet there are a number of obstacles and restrictions that prevent them from being widely accepted in clinical settings. The lack of solid clinical evidence for many products is a significant concern because most studies are constrained by small sample sizes, brief study durations, and inconsistent study designs. The reproducibility and dependability of treatment results are further complicated by inadequate standardization of bioactive substances and raw material variability (Kumar et al., 2017).

Quality and safety concerns are also major obstacles. Nutraceuticals are subject to fewer strict regulations than medicines, which raises the possibility of contamination, adulteration, mislabeling, and uneven potency. Furthermore, overuse or improper use might result in negative side effects or interactions with traditional medications, especially in susceptible groups like the elderly and people with long-term illnesses (Izzo & Ernst, 2009; Geller et al., 2015).

Another significant issue is bioavailability, since many nutraceuticals have poor solubility, stability, or absorption, which lowers their clinical efficacy. Advanced delivery systems create questions about cost, long-term safety, and dose optimization, even though they can solve these problems. All of these difficulties show that in order to guarantee the safe and efficient incorporation of nutraceuticals into evidence-based healthcare, more robust regulatory frameworks, standardized formulations, and carefully planned clinical trials are required (Shahidi, 2012).

12. Conclusion

Nutraceuticals, which provide therapeutic and preventive advantages for a range of chronic and lifestyle-related disorders, occupy a promising position at the nexus of nutrition and medicine. Advanced delivery systems like nanoformulations and microencapsulation enhance stability and bioavailability, while bioactive substances like polyphenols, carotenoids, fatty acids, probiotics, and herbal extracts have demonstrated quantifiable effects in gastrointestinal, metabolic, neurodegenerative, and cardiovascular disorders. However, their full clinical potential is limited by issues such as fragmented regulatory control, possible toxicity, contradictory clinical data, unpredictability in raw materials, and drug-nutraceutical interactions. With trends in fortified functional foods, individualized nutrition, and sustainable bioactive sources, the market is changing quickly. This underscores the need for standardization, harmonized regulation, and thorough scientific validation. To properly utilize nutraceuticals in preventive healthcare and global wellness, future research must focus on

long-term human trials, mechanistic studies, and customized techniques, along with robust quality control and consumer education.

13. Acknowledgments

The authors would like to thank their institution and colleagues for their support and guidance during the preparation of this review.

14. Conflict Of Interest

No authors declared Conflict of Interest.

15. References

- Abdelhamid, A. S., Brown, T. J., Brainard, J. S., et al. (2018). Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews*, 7, CD003177. https://doi.org/10.1002/14651858.CD003177.pub3
- Aggarwal, B. B., & Shishodia, S. (2006). Molecular targets of dietary agents for prevention and therapy of cancer. *Biochemical Pharmacology*, 71(10), 1397–1421. https://doi.org/10.1016/j.bcp.2006.02.009
- Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., et al. (2013). Liposome: Classification, preparation, and applications. *Nanoscale Research Letters*, 8(1), 102. https://doi.org/10.1186/1556-276X-8-102
- Allen, L., de Benoist, B., Dary, O., & Hurrell, R. (2006). *Guidelines on food fortification with micronutrients*. WHO & FAO.
- Anal, A. K., & Singh, H. (2007). Recent advances in microencapsulation of probiotics. *Trends in Food Science & Technology*, 18(5), 240–251. https://doi.org/10.1016/j.tifs.2007.01.004
- Avenell, A., Mak, J. C., & O'Connell, D. (2014). Vitamin D and vitamin D analogues for preventing fractures. *Cochrane Database of Systematic Reviews*, 4, CD000227. https://doi.org/10.1002/14651858.CD000227.pub4
- Baur, J. A., & Sinclair, D. A. (2006). Therapeutic potential of resveratrol. *Nature Reviews Drug Discovery*, 5(6), 493–506. https://doi.org/10.1038/nrd2060
- Bhattacharyya, S., Sood, S., & Ghosh, S. (2018). Quality control and standardization of herbal nutraceuticals. *Phytochemistry Reviews*, 17(3), 631–648. https://doi.org/10.1007/s11101-018-9555-2
- Biesalski, H. K. (2016). Nutraceuticals: Between food and drug. *Pharmacological Research*, 103, 1–3. https://doi.org/10.1016/j.phrs.2015.10.020

- Biesalski, H. K. (2017). Nutraceuticals: Definitions, classification, and mechanisms of action. *Molecular Nutrition & Food Research*, 61(1), 1600505. https://doi.org/10.1002/mnfr.201600505
- Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes. *Biochemical Society Transactions*, 45(5), 1105–1115. https://doi.org/10.1042/BST20160474
- Calder, P. C. (2020). Nutrition, immunity and COVID-19. *BMJ Nutrition, Prevention & Health*, 3(1), 74–92. https://doi.org/10.1136/bmjnph-2020-000085
- Cani, P. D., Delzenne, N. M., Amar, J., & Burcelin, R. (2009). Gut microbiota and metabolic disorders. *Gastroenterology*, 137(5), 1716–1726. https://doi.org/10.1053/j.gastro.2009.08.016
- Celis-Morales, C., Livingstone, K. M., Marsaux, C. F. M., et al. (2015). Personalized nutrition and health outcomes. *Nutrition Reviews*, 73(8), 460–475. https://doi.org/10.1093/nutrit/nuv014
- Chaudhary, A., Nagaich, U., Gulati, N., Sharma, V. K., & Khosa, R. L. (2011). Enhancement of solubility and bioavailability. *Journal of Advanced Pharmaceutical Technology & Research*, 2(1), 32–67.
- Davies, K. M. (2007). Genetic modification for plant nutraceuticals. *Trends in Food Science & Technology*, 18(3), 121–128. https://doi.org/10.1016/j.tifs.2006.10.003
- Didari, T., Mozaffari, S., Nikfar, S., & Abdollahi, M. (2015). Probiotics in irritable bowel syndrome. *World Journal of Gastroenterology*, 21(10), 3072–3084. https://doi.org/10.3748/wjg.v21.i10.3072
- Fenech, M., El-Sohemy, A., Cahill, L., et al. (2011). Nutrigenetics and nutrigenomics. *Journal of Nutrigenetics and Nutrigenomics*, 4(2), 69–89. https://doi.org/10.1159/000327772
- Ganesan, A. R., Tiwari, U., & Rajauria, G. (2020). Seaweed nutraceuticals. *Food Science & Nutrition*, 8(9), 4591–4604. https://doi.org/10.1002/fsn3.1815
- Geller, A. I., Shehab, N., Weidle, N. J., et al. (2015). Adverse events related to dietary supplements. *New England Journal of Medicine*, 373(16), 1531–1540. https://doi.org/10.1056/NEJMsa1504267
- Gibson, G. R., Hutkins, R., Sanders, M. E., et al. (2017). ISAPP consensus on prebiotics. *Nature Reviews Gastroenterology & Hepatology*, 14(8), 491–502. https://doi.org/10.1038/nrgastro.2017.75
- Gupta, S. C., Patchva, S., Koh, W., & Aggarwal, B. B. (2012). Curcumin and its biological activities. *Clinical and Experimental Pharmacology and Physiology*, 39(3), 283–299. https://doi.org/10.1111/j.1440-1681.2011.05648.x
- Halliwell, B., & Gutteridge, J. M. C. (2015). *Free radicals in biology and medicine* (5th ed.). Oxford University Press.

- Hill, C., Guarner, F., Reid, G., et al. (2014). Probiotics consensus statement. *Nature Reviews Gastroenterology & Hepatology*, 11(8), 506–514. https://doi.org/10.1038/nrgastro.2014.66
- Holick, M. F. (2007). Vitamin D deficiency. *New England Journal of Medicine*, 357(3), 266–281. https://doi.org/10.1056/NEJMra070553
- Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007). Nrf2 pathway and chemoprevention. *Annual Review of Pharmacology and Toxicology*, 47, 89–116. https://doi.org/10.1146/annurev.pharmtox.46.120604.141046
- Korhonen, H., & Pihlanto, A. (2006). Bioactive peptides. *International Dairy Journal*, 16(9), 945–960. https://doi.org/10.1016/j.idairyj.2005.10.012
- Kumar, N., Singh, P., & Sharma, R. (2017). Regulatory challenges and safety concerns. *Journal of Dietary Supplements*, 14(6), 667–685. https://doi.org/10.1080/19390211.2017.1338147
- Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. (2004). Polyphenols: Food sources and bioavailability. *American Journal of Clinical Nutrition*, 79(5), 727–747. https://doi.org/10.1093/ajcn/79.5.727
- McClements, D. J. (2018). Enhancing nutraceutical bioavailability. *Annual Review of Food Science and Technology*, 9, 111–133. https://doi.org/10.1146/annurev-food-030117-012716
- Mozaffarian, D., & Wu, J. H. Y. (2011). Omega-3 fatty acids and cardiovascular disease. *Journal of the American College of Cardiology*, 58(20), 2047–2067. https://doi.org/10.1016/j.jacc.2011.06.063
- Pandey, K. B., & Rizvi, S. I. (2009). Plant polyphenols as antioxidants. *Oxidative Medicine and Cellular Longevity*, 2(5), 270–278. https://doi.org/10.4161/oxim.2.5.9498
- Rao, A. V., & Rao, L. G. (2007). Carotenoids and human health. *Pharmacological Research*, 55(3), 207–216. https://doi.org/10.1016/j.phrs.2007.01.012
- Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019). Probiotics and prebiotics in intestinal health. *Nature Reviews Gastroenterology & Hepatology*, 16(10), 605–616. https://doi.org/10.1038/s41575-019-0173-3
- Shahidi, F. (2012). Nutraceuticals and functional foods. *Journal of Food and Drug Analysis*, 20(1), 226–230.
- Tang, G., Qin, J., Dolnikowski, G. G., Russell, R. M., & Grusak, M. A. (2012). Golden Rice as vitamin A source. *American Journal of Clinical Nutrition*, 96(3), 658–664. https://doi.org/10.3945/ajcn.111.030775

GLOBAL JOURNAL OF PHARMACEUTICAL AND SCIENTIFIC RESEARCH
GJPSR